Ngar Yee Louie has bought MAIA on 4 days since Aug 2022

Adelina Louie Ngar Yee is an independent director at MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, particularly ateganosine (THIO) for non-small cell lung cancer.( She serves as Chair of the Nominating and Corporate Governance Committee.( Ms. Louie has demonstrated strong confidence in MAIA by making significant investments, including purchasing 81,699 shares at $1.224 on December 22, 2025, increasing her direct ownership to 1,248,888 shares, along with stock options, and participating in private placements.(

Ms. Louie brings over 30 years of experience with the HSBC Group, primarily in Global Banking and Markets, including investment and securities management, asset management, global research, and leadership in Group Internal Audit across Latin America, Asia Pacific, and the UK.( Born and educated in Hong Kong, she joined HSBC as an executive trainee, became an International Manager in 1996, and held key roles in Hong Kong, the Philippines, Indonesia, Taiwan, the US, UK, and Latin America, driving business re-engineering, turnarounds, and setups.( Prior to joining MAIA's board in April 2020, she served as Group Chief Operating Officer of Group Internal Audit at HSBC.(

Written by Perplexity from public sources.